Tim Boreham revisits Imagion Biosystems’ potential in this 5-1/2 page article profiling the company and discussing its recent milestones.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce